MassBioDrive Launch

January 19, 2022 5:30 PM - 7:00 PM

Virtual

Add to Calendar 1/19/2022 5:30:00 PM 1/19/2022 7:00:00 PM MassBioDrive Launch

Join us on January 19 to celebrate the launch of MassBioDrive and network with MassBio's innovation ecosystem! This virtual program will feature:
 

  • A fireside chat with Jen Nwankwo, Founder & CEO of 1910 Genetics and Chris Garabedian, Chairman and CEO of Xontogeny, moderated by Kendalle Burlin O'Connell, President and COO of MassBio
  • Topic-specific networking and Q&A about the spring 2022 application process for MassBioDrive
 

MassBioDrive is a next generation biotech accelerator designed to advance breakthrough science and provide opportunities to innovators from all parts of the life science ecosystem. Over the course of an intensive eight-week program, selected startups will participate in six business-focused curriculum modules taught by seasoned industry experts, partner with a small, dedicated group of mentors, and receive access to networking events, an end-of-program Demo Day to help grow visibility in the ecosystem, equity-free prizes, and 1:1 partnering meetings at MassBio’s bi-annual Partnering Week.

Apply for Drive's Spring 2022 cohort here. 

 Virtual,
Chairman and CEO, Xontogeny
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund which supports early-stage companies with Series A investments across biotech, medtech and healthtech. Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005. Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. Chris is also on the Board of Directors of MassBio, served as a Senior Advisor for the Boston Consulting Group and is a member of the Corporate Relations Board for the Keck Graduate Institute.

Brought to you by